HC Wainwright Estimates XOMA’s Q1 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – HC Wainwright issued their Q1 2025 earnings per share estimates for XOMA in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings per share of ($0.20) for the quarter. HC Wainwright currently has a “Buy” rating and a $104.00 target price on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.

Separately, StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Friday.

XOMA Price Performance

XOMA stock opened at $20.88 on Friday. The firm has a 50 day moving average price of $24.37 and a 200-day moving average price of $27.14. XOMA has a 52-week low of $19.92 and a 52-week high of $35.00. The firm has a market capitalization of $250.12 million, a price-to-earnings ratio of -6.00 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA) last posted its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The business had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

Institutional Investors Weigh In On XOMA

A number of large investors have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets raised its position in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. New York State Common Retirement Fund raised its position in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the period. Wells Fargo & Company MN raised its position in XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,183 shares during the period. Bank of America Corp DE raised its position in XOMA by 34.7% in the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,009 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new stake in XOMA in the 4th quarter worth about $206,000. Institutional investors own 95.92% of the company’s stock.

Insiders Place Their Bets

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.20% of the stock is currently owned by insiders.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.